Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
32.76
+0.36 (1.11%)
At close: Feb 6, 2026, 4:00 PM EST
33.40
+0.64 (1.95%)
After-hours: Feb 6, 2026, 7:49 PM EST
Castle Biosciences Employees
Castle Biosciences had 823 employees as of September 30, 2025. The number of employees increased by 113 or 15.92% compared to the same quarter last year.
Employees
823
Change
113
Growth
15.92%
Revenue / Employee
$417,412
Profits / Employee
-$14,868
Market Cap
955.93M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 823 | 113 | 15.92% | 823 | 0 |
| Jun 30, 2025 | 798 | 95 | 13.51% | 798 | 0 |
| Mar 31, 2025 | 784 | 146 | 22.88% | 784 | 0 |
| Dec 31, 2024 | 761 | 151 | 24.75% | 761 | 0 |
| Sep 30, 2024 | 710 | 123 | 20.95% | 710 | 0 |
| Jun 30, 2024 | 703 | 121 | 20.79% | 703 | 0 |
| Mar 31, 2024 | 638 | 95 | 17.50% | 638 | 0 |
| Dec 31, 2023 | 610 | 67 | 12.34% | 610 | 0 |
| Sep 30, 2023 | 587 | 70 | 13.54% | 587 | 0 |
| Jun 30, 2023 | 582 | 100 | 20.75% | 582 | 0 |
| Dec 31, 2022 | 543 | 198 | 57.39% | 542 | 1 |
| Sep 30, 2022 | 517 | 206 | 66.24% | 517 | 0 |
| Jun 30, 2022 | 482 | 190 | 65.07% | 482 | 0 |
| Dec 31, 2021 | 345 | 144 | 71.64% | 342 | 3 |
| Sep 30, 2021 | 311 | 110 | 54.73% | 311 | 0 |
| Jun 30, 2021 | 292 | - | - | 292 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| OPKO Health | 2,997 |
| Neogen | 2,974 |
| Myriad Genetics | 2,700 |
| NeoGenomics | 2,200 |
| Fulgent Genetics | 1,313 |
| GeneDx Holdings | 1,000 |
| Veracyte | 824 |
| Burning Rock Biotech | 674 |
CSTL News
- 3 days ago - Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 - GlobeNewsWire
- 4 days ago - Allspring Emerging Growth Fund Q4 2025 Performance Review - Seeking Alpha
- 4 days ago - Wasatch Micro Cap Fund Q4 2025 Performance Review - Seeking Alpha
- 4 weeks ago - Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results - GlobeNewsWire
- 7 weeks ago - Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma - GlobeNewsWire
- 2 months ago - Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer - GlobeNewsWire
- 2 months ago - Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma - GlobeNewsWire